Immunovant
IMVT
197 hedge funds and large institutions have $1.97B invested in Immunovant in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 82 increasing their positions, 65 reducing their positions, and 35 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 65
2.69% more ownership
Funds ownership: 48.45% → 51.14% (+2.7%)
3% more call options, than puts
Call options by funds: $24.3M | Put options by funds: $23.6M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less funds holding
Funds holding: 209 → 197 (-12)
13% less capital invested
Capital invested by funds: $2.27B → $1.97B (-$300M)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.4M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$68M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$46.2M |
| 4 |
AC
Armistice Capital
New York
|
+$35.1M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$44.7M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$34.1M |
| 3 |
PA
Perceptive Advisors
New York
|
-$29.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$26.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.4M |
IMVT Hedge Fund Activity: Q2 2024 in Review
197 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2024, worth a combined $1.97B — down 13% from $2.27B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of IMVT and 25 opened new positions — a net loss of 10 holders — while 65 trimmed existing stakes and 82 added.
The largest buyer was Fidelity Investments, adding an estimated $80.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $44.7M sold.
- 197 institutional investors held Immunovant (IMVT) as of Q2 2024, down from 209 in Q1 2024.
- Funds reported $1.97B of Immunovant stock for Q2 2024, down 13% quarter-over-quarter.
- 25 funds opened new Immunovant positions in Q2 2024 and 35 closed out, a net change of -10 holders.
- The largest Immunovant buyer in Q2 2024 was Fidelity Investments, an estimated $80.4M added.
- The largest Immunovant seller in Q2 2024 was Point72 Asset Management, an estimated $44.7M sold.
Based on aggregated 13F filings for Q2 2024.